Atossa Therapeutics, Inc. – NASDAQ:ATOS
Atossa Therapeutics stock price today
$0.76
-0.22
-22.54%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 1 hour
Atossa Therapeutics stock price monthly change
-25.11%
month
Atossa Therapeutics stock price quarterly change
-25.11%
quarter
Atossa Therapeutics stock price yearly change
+8.71%
year
Atossa Therapeutics key metrics
Market Cap | 123.76M |
Enterprise value | N/A |
P/E | -3.52 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 794.21 |
PEG ratio | 0.21 |
EPS | -0.23 |
Revenue | N/A |
EBITDA | -28.24M |
Income | -29.69M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAtossa Therapeutics stock price history
Atossa Therapeutics stock forecast
Atossa Therapeutics financial statements
| Jun 2023 | 0 | -9.83M | |
|---|---|---|---|
| Sep 2023 | 0 | -6.22M | |
| Dec 2023 | 0 | -7.75M | |
| Mar 2024 | 0 | -5.87M |
| Dec 2023 | 0 | -7.75M | |
|---|---|---|---|
| Mar 2024 | 0 | -5.87M | |
| Sep 2025 | 0 | -7.51M | |
| Dec 2025 | 0 | -7.51M |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 108355000 | 3.47M | 3.21% |
|---|---|---|---|
| Sep 2023 | 101695000 | 3.44M | 3.39% |
| Dec 2023 | 96252000 | 5.23M | 5.44% |
| Mar 2024 | 91087000 | 5.32M | 5.85% |
| Jun 2023 | -4.46M | -13K | 0 |
|---|---|---|---|
| Sep 2023 | -3.88M | -1K | -1.47M |
| Dec 2023 | -5.57M | 0 | 0 |
| Mar 2024 | -4.69M | -6K | 204K |
Atossa Therapeutics alternative data
| Aug 2023 | 11 |
|---|---|
| Sep 2023 | 11 |
| Oct 2023 | 11 |
| Nov 2023 | 11 |
| Dec 2023 | 11 |
| Jan 2024 | 11 |
| Feb 2024 | 11 |
| Mar 2024 | 11 |
| Apr 2024 | 11 |
| May 2024 | 12 |
| Jun 2024 | 12 |
| Jul 2024 | 12 |
Atossa Therapeutics other data
100.00%
0.00%
of ATOS is owned by hedge funds
64
-10
23.26M
-12.59M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jun 2023 | 50000 | 0 |
| Nov 2023 | 0 | 50000 |
| Apr 2024 | 25000 | 0 |
| Patent |
|---|
Application Filling date: 20 Jan 2022 Issue date: 4 Aug 2022 |
Application Filling date: 2 Jul 2020 Issue date: 9 Jun 2022 |
Application Filling date: 11 Mar 2019 Issue date: 4 Mar 2021 |
Application Filling date: 20 Dec 2018 Issue date: 7 Jan 2021 |
Application Filling date: 10 Sep 2018 Issue date: 27 Aug 2020 |
Application Filling date: 10 Sep 2018 Issue date: 9 Jul 2020 |
Application Filling date: 10 Sep 2018 Issue date: 2 Jul 2020 |
| Quarter | Transcript |
|---|---|
| Q2 2023 14 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Q3 2016 14 Nov 2016 | Q3 2016 Earnings Call Transcript |
| Q2 2016 15 Aug 2016 | Q2 2016 Earnings Call Transcript |
| Q1 2016 8 May 2016 | Q1 2016 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Steven C. Quay (1951) Chairman, Chief Executive Officer & Pres | $944,570 |
Mr. Kyle Guse CPA, Esq., CPA (1964) Chief Financial Officer, Gen. Counsel & Sec. | $624,130 |
-
What's the price of Atossa Therapeutics stock today?
One share of Atossa Therapeutics stock can currently be purchased for approximately $0.76.
-
When is Atossa Therapeutics's next earnings date?
Unfortunately, Atossa Therapeutics's (ATOS) next earnings date is currently unknown.
-
Does Atossa Therapeutics pay dividends?
No, Atossa Therapeutics does not pay dividends.
-
How much money does Atossa Therapeutics make?
Atossa Therapeutics has a market capitalization of 123.76M.
-
What is Atossa Therapeutics's stock symbol?
Atossa Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "ATOS".
-
What is Atossa Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Atossa Therapeutics?
Shares of Atossa Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Atossa Therapeutics's key executives?
Atossa Therapeutics's management team includes the following people:
- Dr. Steven C. Quay Chairman, Chief Executive Officer & Pres(age: 74, pay: $944,570)
- Mr. Kyle Guse CPA, Esq., CPA Chief Financial Officer, Gen. Counsel & Sec.(age: 61, pay: $624,130)
-
How many employees does Atossa Therapeutics have?
As Jul 2024, Atossa Therapeutics employs 12 workers, which is 9% more then previous quarter.
-
When Atossa Therapeutics went public?
Atossa Therapeutics, Inc. is publicly traded company for more then 12 years since IPO on 8 Nov 2012.
-
What is Atossa Therapeutics's official website?
The official website for Atossa Therapeutics is atossatherapeutics.com.
-
Where are Atossa Therapeutics's headquarters?
Atossa Therapeutics is headquartered at 107 Spring Street, Seattle, WA.
-
How can i contact Atossa Therapeutics?
Atossa Therapeutics's mailing address is 107 Spring Street, Seattle, WA and company can be reached via phone at +20 65 880256.
Atossa Therapeutics company profile:
Atossa Therapeutics, Inc.
atossatherapeutics.comExchange:
NASDAQ
Full time employees:
12
Industry:
Biotechnology
Sector:
Healthcare
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
107 Spring Street
Seattle, WA 98104
Seattle, WA 98104
CIK: 0001488039
ISIN: US04962H5063
CUSIP: 04962H506
